干细胞治疗肝脏疾病研究进展*

doi:10.3969/j.issn.1672-5069.2018.01.042

Abstract

Abstract: Stem cells have the ability to undergo self-renewal, proliferation and multi-lineage differentiation. As the most promising source of seed cells, the clinical applications of stem cells have become the focus of attention for years at home and abroad. There have been many reports about the applications of stem cells in treatment of liver diseases,which show the preliminary efficacy and safety. Stem cells therapies will emerge as a new treatment strategy for liver diseases. the progress about stem cells on the following aspects in this article was reviewed,such as the classification of stem cells,cell culture and transplantation,cell tracing in the body and the therapies for various liver diseases.

Key words: Stem cells, Liver diseases, Therapy

Li Shanshan, Hong Feng, Chen Yu. Stem cell therapy in liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 145-148.

References

[1] Trounson A,Mcdonald C. Stem cell therapies in clinical trials: Progress and challenges. Cell Stem Cell,2015,17（1）:11-22.
[2] Turner R,Lozoya O,Wang Y,et al. Human hepatic stem cell and maturational liver lineage biology. Hepatology,2011,53（3）:1035-1045.
[3] Wang B,Zhao L,Fish M,et al. Self-renewing diploid Axin2+ cells fuel homeostatic renewal of the liver. Nature,2015,524（7564）:180-185.
[4] 毕研贞,樊增,陈东风,等. 人肝源性干细胞腹腔移植不同时间对刀豆蛋白A诱导小鼠急性肝损伤保护作用.中华肝脏病杂志,2017,25（3）:201-207.
[5] Teratani T,Yamamoto H,Aoyagi K,et al. Direct hepatic fate specification from mouse embryonic stem cells. Hepatology,2005,41（4）:836-846.
[6] Kwon EM,Connelly JP,Hansen NF,et al. iPSCs and fibroblast subclones from the same fibroblast population contain comparable levels of sequence variations. Proc Natl Acad Sci US A,2017,114（8）:1964-1969.
[7] Wang Y,Qin J,Wang S,et al. Conversion of human gastric epithelial cells to multipotent endodermal progenitors using defined small molecules. Cell Stem Cell,2016,19（4）:449-461.
[8] Kuo TK,Hung SP,Chuang CH,et al. Stem cell therapy for liver disease:parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology,2008,134（7）:2111-2113.
[9] Pan F,Liao N,Zheng Y,et al. Intrahepatic transplantation of adipose-derived stem cells attenuates the progression of non-alcoholic fatty liver disease in rats. Mol Med Rep,2015,12（3）:3725-3733.
[10] Garg V,Garg H,Khan A,et al. Granulocyte colony-stimulating factor mobilizes CD34+,cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology,2012,142（3）:505-512.
[11] Guo L,Zhou Y,Wang S,et al. Epigenetic changes of mesenchymal stem cells in three-dimensional （3D） spheroids. J Cell Mol Med,2014,18（10）:2009-2019.
[12] Li Y,Guo G,Li L,et al. Three-dimensional spheroid culture of human umbilical cord mesenchymal stem cells promotes cell yield and stemness maintenance. Cell Tissue Res,2015,360（2）:297-307.
[13] Chen Q,Utech S,Chen D,et al. Controlled assembly of heterotypic cells in a core-shell scaffold: organ in a droplet. Lab Chip,2016,16（8）:1346-1349.
[14] Nagamoto Y,Takayama K,Ohashi K,et al. Transplantation of a human iPSC-derived hepatocyte sheet increases survival in mice with acute liver failure. J Hepatol,2016,64（5）:1068-1075.
[15] Takebe T,Sekine K,Enomura M,et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature,2013,499（7459）:481-484.
[16] Wang Y,Cui CB,Yamauchi M,et al. Lineage restriction of human hepatic stem cells to mature fates is made efficient by tissue-specific biomatrix scaffolds. Hepatology,2011,53（1）:293-305.
[17] Yan L,Han Y,He Y,et al. Cell tracing techniques in stem cell transplantation. Stem Cell Rev,2007,3（4）:265-269.
[18] Lei H,Nan X,Wang Z,et al. Stem cell labeling with superparamagnetic iron oxide nanoparticles using focused ultrasound and magnetic resonance imaging tracking. J Nanosci Nanotechnol,2015,15（4）:2605-2612.
[19] Herrera MB,Fonsato V,Bruno S,et al. Human liver stem cells improve liver injury in a model of fulminant liver failure.Hepatology,2013,57（1）:311-319.
[20] Shi D,Zhang J,Zhou Q,et al. Quantitative evaluation of human bone mesenchymal stem cells rescuing fulminant hepatic failure in pigs. Gut,2017,66（5）:955-964.
[21] Shi M,Zhang Z,Xu R,et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-
chronic liver failure patients. Stem Cells Transl Med,2012,1（10）:725-731.
[22] Suk KT,Yoon JH,Kim MY,et al. Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis:Phase 2 trial. Hepatology,2016,64（6）:2185-2197.
[23] 于双杰,陈黎明,吕飒,等. 人脐带间充质干细胞治疗失代偿性乙型肝炎肝硬化的安全性与疗效. 中华肝脏病杂志,2016,24（1）:51-55.
[24] Sakisaka M,Haruta M,Komohara Y,et al. Therapy of primary and metastatic liver cancer by human iPS cell-derived myeloid cells producing interferon-β. J Hepatobiliary Pancreat Sci,2017,24（2）:109-119.
[25] Liao N,Pan F,Wang Y,et al. Adipose tissue-derived stem cells promote the reversion of non-alcoholic fatty liver disease: An in vivo study. Int J Mol Med,2016,37（5）:1389-1396.
[26] Wang L,Li J,Liu H,et al. Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis.J Gastroenterol Hepatol,2013,28（S1）:85-92.
[27] Wang L,Han Q,Chen H,et al. Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis. Stem Cells Dev,2014,23（20）:2482-2489.
[28] Chen Y,Chen S,Liu LY,et al. Mesenchymal stem cells ameliorate experimental autoimmune hepatitis by activation of the programmed death 1 pathway. Immunol Lett,2014,162（2）:222-228.

Stem cell therapy in liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	Gao Lei, Cao Lei, Wang Ruifang, et al.. Protective effect of human umbilical cord mesenchymal stem cell transplantation on alcoholic liver injury in rats [J]. Journal of Practical Hepatology, 2019, 22(6): 812-815.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[6]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[7]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[8]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[9]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[10]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[11]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[12]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[13]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[14]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[15]	Song Haiyan, Chen Xi, Zhang Junfei, et al. Application of vorionazole in the treatment of patients with liver failure complicated by pulmonary fungal infection [J]. Journal of Practical Hepatology, 2019, 22(5): 676-679.